Skip to main content
. 2020 Feb 18;21(4):1384. doi: 10.3390/ijms21041384
ACh Acetylcholine
Akt Protein kinase B
Apamin Small conductance calcium-activated potassium channel inhibitor
ANX-A Annexin A1, endogenous ligand for FPR
cAMP Cyclic adenosine monophosphate
CB Citrate buffer
Cmpd17b Compound 17b, agonist of FPR1/2
Cmpd43 Compound 43, agonist of FPR1/2
COX 1 Cyclooxygenase-1
COX 2 Cyclooxygenase-2
Cq Quantification cycle
DMSO Dimethyl sulfoxide
EDH Endothelium-derived hyperpolarization
Emax Maximum contraction
ERK1/2 Extracellular signal-regulated kinases 1/2
FPR Formyl peptide receptor family
FPR1 Formyl peptide receptor 1
FPR2 Formyl peptide receptor 2
Glibenclamide ATP-sensitive potassium (KATP) channel blocker
HbA1c Glycated haemoglobin A1c
IKca Intermediate conductance calcium-activated potassium channel
KCaB Combination of inhibitors (Apamin and TRAM34)
Indo Indomethacin
L-NAME nitric oxide synthase (NOS) inhibitor, L-NG-Nitroarginine methyl ester
LxA4 Lipoxin 4
NGS Normal goat serum
Nifedipine Calcium channel blocker
NO Nitric oxide
NOS Nitric oxide synthase
ODQ Soluble guanylate cyclase inhibitor, 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one
PBS Phosphate buffered saline
pEC50 Sensitivity
PGI2 Prostacyclin
PSS Physiological saline solution
PTGIR Prostaglandin I2 receptor
PTGIS Prostacyclin synthase
Rn18s 18s Ribosomal RNA
Rmax Maximum relaxation
SKca Small conductance calcium-activated potassium channel
SNP Sodium nitroprusside
STZ Streptozotocin
TRAM34 Intermediate conductance calcium-activated potassium channel inhibitor, 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole
U46619 Thromboxane A2 mimetic